Clinical Trial Update: A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI [Phase 2]

View source ↗

Summary

A phase 2 study evaluating alprostadil liposome injection for preventing contrast-induced acute kidney injury was terminated before completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Acute Kidney Injury

Drugs mentioned

• Alprostadil Liposomes Injection (alprostadil liposome injection)

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Contrast-induced Acute Kidney Injury | Phase 2 | Status: TERMINATED